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Background. Antiplatelet treatment with aspirin is well established as secondary prophylaxis after a transient ischemic attack or minor ischemic stroke, but the effect of aspirin treatment on the course of carotid atherosclerosis is unknown. We investigated the effect of aspirin on the initial stages of carotid atherosclerosis. Methods and Results. Patients were recruited from a prospective, randomized, double-blind clinical trial to compare two doses of aspirin (900 mg versus 50 mg daily) with regard to restenoses after lower limb angioplasty. Of the 383 patients admitted to the angioplasty trial, 27 patients with 104 small carotid atheroma (<50%o lumen narrowing) were examined at entry and after 1 year of aspirin treatment with the use of a high-resolution ultrasound duplex system. Disease progression and regression were defined by a change of maximal plaque area (as measured by longitudinal ultrasound sections) of more than 2 SDs of the method. The change in plaque area was significantly different for the treatment groups: Average plaque size remained unchanged after treatment with 900 mg aspirin daily but increased markedly after treatment with 50 mg aspirin daily (p=0.011). There were significantly more lesions in the 50-mg group showing progression than in the 900-mg group ( Ultrasonic disappearance of a lesion was observed only in the 900-mg group in nine cases (seven soft plaques and two ulcerative plaques,p=0.018). The six patients on 50 mg aspirin who continued smoking during the study showed significantly more progression compared with the seven nonsmokers in the 50-mg group ( There is strong evidence that the natural course of peripheral arterial occlusive disease can be slowed under long-term treatment with aspirin,4 but the effect of aspirin treatment on the course of carotid atherosclerosis is unknown. Low doses of aspirin might be advantageous because the synthesis of the proaggregatory thromboxane A2 in platelets is inhibited to a greater extent than the production of the antiaggregatory prostacyclin in the vessel wall. 5, 6 High-resolution ultrasound duplex system analysis of small carotid atheroma revealed spontaneous progression as well as regression after an 18-month follow-up period.7 In another duplex ultrasound study on patients with inherited hypercholesterolemia, the reduction of carotid plaque volume correlated with low density lipoprotein elimination.8 It was our aim to study the effect of different doses of aspirin on progression and regression of small carotid atheroma.
Methods

Eligible Patients
Patients were recruited from a prospective, randomized, double-blind clinical trial of high-versus low-dose aspirin treatment to prevent restenoses of the lower limb arteries after percutaneous transluminal angioplasty. The Low Dose Aspirin Trial on Restenosis After Angioplasty (LARA)* was performed to study the efficacy and side effects of a daily 50-mg dose of aspirin compared with a 900-mg dose. Primary outcome event was the angiographically proven occurrence of restenosis at the angioplasty site; other clinical end points were the occurrence of intolerable side effects, lower limb ischemia due to lesions distant to the angioplasty site, death, stroke, and myocardial infarction. We expected a *Details will be reported separately and are available from Dr. Ranke. Ethical approval was given by the hospital ethics committee. In accordance to the Declaration of Helsinki, all patients gave their written consent after receiving extensive information about the background and purpose of the study by discussion as well as through a printed information sheet.
Randomization and Treatment
Blocked randomization was performed with a block size of 4 using random permutated blocks. Coded aspirin was prepared by the pharmacy, and blinded treatment allocation was obtained by central randomization. The randomization code was kept sealed in numbered opaque envelopes and was unknown to any of the participants in the study. A total of 383 patients were admitted to the angioplasty trial, and 40 patients were assigned for concurrent participation in the carotid sonography study.
Treatment with antiplatelet drugs other than the study aspirin was not permitted; agents improving tissue perfusion (e.g., pentoxifylline) were withdrawn. Accompanying medication was left unchanged during the study and included lipid-lowering drugs in four patients (two in the 900-mg group and two in the 50-mg group), nifedipine (four patients versus three patients), diuretics (two patients versus four patients), and antihypertensive drugs (three patients versus one patient).
Ultrasound Examination
Carotid sonography was performed at entry and again 12 months later by an experienced investigator (C.R.) following a standardized protocol. We used a duplex system with a high-resolution B-scan imaging device (7.5 Of the 40 patients initially assigned for participation in the carotid ultrasound study, 13 patients were withdrawn from the LARA trial (Table 1) . Compliance testing was performed 1, 3, 6, 9, and 12 months after angioplasty by marking the study medication with riboflavin (urine fluorescence) and by measurement of platelet aggregation. Duplex system analysis of 27 patients (19 men and eight women; age range, 33-79 years; mean age, 57.6 years) could be performed at entry and after 12 months and revealed a total of 104 plaques.
Statistical Analysis
The statistical program BMDP3V (BMDP Statistical Software, Inc., Los Angeles, Calif.) was used with a microcomputer. The comparison of the two treatment remained unchanged after daily treatment with 900 mg aspirin daily but increased markedly after treatment with 50 mg aspirin ( Figure 1 and Table 4 ). The difference in plaque size change between the two groups was 0.05 cm2 (95% confidence interval, 0.01 to 0.09 cm2). The total plaque area was calculated as the sum of all individual plaques per patient (mean+SD, 2.9±1.8 plaques per patient; range, one to eight). Comparable to the individual plaque analysis, the total plaque area increased markedly in the 50-mg group and remained constant after treatment with 900 mg aspirin daily ( Figure 2 and Table 5 ) (p=0.050, two-group t test). Thirty-six plaques (35%) showed progression, 22 plaques (21%) showed regression, and 46 (44%) remained unchanged. Simultaneous progression and regression of disease were observed in eight patients (30%; Table 6 ). There were significantly more plaques in the 50-mg aspirin group showing disease progression than in the 900-mg aspirin group (p=0.025; Figure 3 ).
At least one risk factor (smoking, hypertension, hyperlipidemia, diabetes, hyperuricemia) was recorded in 74% (20 of 27) of our patients. The presence of one or more risk factors was associated with an increased rate of disease progression in the 50-mg aspirin group (p=0.06; Table 7 ). The most important risk factor with regard to disease progression was smoking: The six patients on 50 mg aspirin who continued smoking during the study showed significantly more progression compared with the seven nonsmokers in the 50-mg group (p=0.038; Table 8 ). The other risk factors accentuated the difference between the treatment groups with regard to progression and regression of disease.
After 12 months, there were seven new lesions (five soft plaques and two fibrous plaques) in the 900-mg aspirin group and five new lesions in the 50-mg aspirin group (three soft plaques, one fibrous plaque, and one ulcerative plaque; p=NS). Ultrasonic disappearance of a lesion was recorded only in the 900-mg aspirin group in nine cases (seven soft plaques and two ulcerative plaques;p=0.018). In both treatment groups, healing of Discussion This is the first prospective, randomized, doubleblind study of the effect of different aspirin doses on progression and regression of small carotid atheroma. Our patients were participants in the LARA trial who had peripheral arterial occlusive disease treated by percutaneous transluminal angioplasty. The results of our duplex ultrasound study on a subgroup of these patients with small carotid atheroma showed that highdose aspirin inhibited progression of carotid plaques.
Previous studies on the natural course of nonstenotic carotid atheromatous lesions using high-resolution duplex system analysis had shown disease progression and regression after 6 months in 24% and 10%1O and after 18 months in 30% and 19%.7 The duplex ultrasound study of Roederer et al,1' included medium-and highgrade carotid stenoses and revealed disease progression in 25% and regression in only 2% after 12 months. The proportion of patients who showed progression was not affected by antiplatelet treatment with aspirin or dipyridamole. Subsequent follow-up studies on stenoses of the carotid artery, including medium-to high-grade diameter reduction, showed comparable rates of pro- The superiority of the higher-dose aspirin regimen in our study with regard to progression and regression of small carotid atheroma is difficult to explain. Low-dose aspirin inhibits proaggregatory thromboxane to a greater extent than the antiaggregatory prostacyclin,5'6 and 50 mg/day may be the best dose.23 '24 On the other hand, in an animal study on the antithrombotic action of aspirin,25 another antithrombotic effect of aspirin independent of platelet cyclooxygenase inhibition was described that required high doses of 20 mg/kg per day. In addition to its antiplatelet activity, aspirin may affect the course of atherosclerosis, acting as an anti-inflammatory agent at higher doses. The formation of atherosclerotic plaques has some features in common with the inflammatory process,26 and the role of macrophages in atherogenesis has been discussed.27 In an animal study,8 the rate of plaque initiation or progression was reduced after treatment with an anti-inflammatory steroid. An ultrasonographic follow-up study on patients with carotid atherosclerosis revealed a close association of increased white blood cell count with accelerated progression of disease.29 Our findings appear to be inconsistent with the results of a large clinical trial3 revealing a low dose of aspirin (30 mg) being effective in the secondary prevention of vascular events after a transient ischemic attack or minor ischemic stroke. The reduction of embolism from high-grade carotid stenoses after treatment with low-dose aspirin probably is an effect of thromboxane synthesis inhibition, but higher aspirin doses may suppress carotid plaque growth by mechanisms independent of its antiplatelet effects.
In the presence of risk factors, an endothelial injury leads to migration and proliferation of smooth muscle cells and fibrous plaque formation according to the revised response-to-injury hypothesis2'0 Important risk factors for carotid atherosclerosis are smoking,11 '29'31'32 hypercholesterolemia,829 diabetes mellitus,1'32 and hypertension.13'32 The presence of risk factors was associated with an increased rate of disease progression in the 50-mg group of our study. After treatment with 50 mg aspirin daily, the patients who had continued smoking during our study showed significantly more disease progression compared with the patients who had stopped smoking.
Our study was not placebo controlled, and the majority of our patients exhibited at least one risk factor. Because life-style changes without medical treatment were able to change coronary atherosclerosis toward regression,22 future studies on the course of carotid atherosclerosis should evaluate the effect of improvements in risk factors in comparison to treatment with aspirin. Another possible limitation of our study was the small number of patients who were assigned for participation in the carotid sonography study. The patient-topatient comparison only approached significance (p=0.05), but the additional analysis of individual plaques is justified because eight patients (30%) showed progression and regression simultaneously (Table 6) . Our results are confined to patients with small atheromatous plaques and might not hold true for those with >50% carotid artery stenoses. The relatively high proportion of withdrawals in our study is a possible cause of selection bias because only patients who took aspirin reliably for 12 months were included in the analysis. Most withdrawals were due to noncompliance or gastrointestinal side effects (11 of 13 patients); two patients had vascular events. Both events (stroke and restenosis 
